Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.

Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yun-An Lim, Amandine Grimm, Maria Giese, Ayikoe Guy Mensah-Nyagan, J Ernest Villafranca, Lars M Ittner, Anne Eckert, Jürgen Götz
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
R
Q
Acceso en línea:https://doaj.org/article/939330ec41c24ee59baa3fd8d8832f0f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:939330ec41c24ee59baa3fd8d8832f0f
record_format dspace
spelling oai:doaj.org-article:939330ec41c24ee59baa3fd8d8832f0f2021-11-18T07:32:30ZInhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.1932-620310.1371/journal.pone.0028887https://doaj.org/article/939330ec41c24ee59baa3fd8d8832f0f2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22174920/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports indicate that Aβ may also interact directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial dysfunction occurs early in AD, and Aβ's toxicity is in part mediated by inhibition of ABAD as shown previously with an ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role of ABAD in Aβ toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Aβ-ABAD interaction in a pull-down assay while it also prevented the Aβ42-induced down-regulation of ABAD activity, as measured by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Aβ42 toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Aβ42-induced impairment of mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our previous finding of shared aspects of the toxicity of Aβ and human amylin (HA), with the latter forming aggregates in Type 2 diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out.Yun-An LimAmandine GrimmMaria GieseAyikoe Guy Mensah-NyaganJ Ernest VillafrancaLars M IttnerAnne EckertJürgen GötzPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 12, p e28887 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Yun-An Lim
Amandine Grimm
Maria Giese
Ayikoe Guy Mensah-Nyagan
J Ernest Villafranca
Lars M Ittner
Anne Eckert
Jürgen Götz
Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
description Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports indicate that Aβ may also interact directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial dysfunction occurs early in AD, and Aβ's toxicity is in part mediated by inhibition of ABAD as shown previously with an ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role of ABAD in Aβ toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Aβ-ABAD interaction in a pull-down assay while it also prevented the Aβ42-induced down-regulation of ABAD activity, as measured by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Aβ42 toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Aβ42-induced impairment of mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our previous finding of shared aspects of the toxicity of Aβ and human amylin (HA), with the latter forming aggregates in Type 2 diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out.
format article
author Yun-An Lim
Amandine Grimm
Maria Giese
Ayikoe Guy Mensah-Nyagan
J Ernest Villafranca
Lars M Ittner
Anne Eckert
Jürgen Götz
author_facet Yun-An Lim
Amandine Grimm
Maria Giese
Ayikoe Guy Mensah-Nyagan
J Ernest Villafranca
Lars M Ittner
Anne Eckert
Jürgen Götz
author_sort Yun-An Lim
title Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
title_short Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
title_full Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
title_fullStr Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
title_full_unstemmed Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
title_sort inhibition of the mitochondrial enzyme abad restores the amyloid-β-mediated deregulation of estradiol.
publisher Public Library of Science (PLoS)
publishDate 2011
url https://doaj.org/article/939330ec41c24ee59baa3fd8d8832f0f
work_keys_str_mv AT yunanlim inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT amandinegrimm inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT mariagiese inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT ayikoeguymensahnyagan inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT jernestvillafranca inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT larsmittner inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT anneeckert inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
AT jurgengotz inhibitionofthemitochondrialenzymeabadrestorestheamyloidbmediatedderegulationofestradiol
_version_ 1718423301344198656